ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)

SEK 20.6

(-4.63%)

Market Cap (In SEK)

45.36 Million

Revenue (In SEK)

7.05 Million

Net Income (In SEK)

-91.4 Million

Avg. Volume

430.14 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
17.84-140.15048
PE
-
EPS
-
Beta Value
1.651
ISIN
SE0008348262
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Bent U. Frandsen MSc
Employee Count
-
Website
https://www.expres2ionbio.com
Ipo Date
2016-07-29
Details
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.